Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 and Cetuximab β in KRAS G12C-mutated Metastatic Colorectal Cancer
NCT06959589Phase 2Enrolling by invitation
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fulzerasib in colorectal cancer (CRC) (2 cohorts), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 8 weeks. Started May 2025; status: enrolling by invitation.
02
Drugs
fulzerasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06959589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959589.